Dare Bioscience, Inc.

Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast cancer The program addresses non-hormonal approaches to women's sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6% Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Society's 2026 Annual Meeting SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced its premier sponsorship of Managing Menopause After Breast Cancer, a continuing medical education (CME) program presented by HERmedicine and the OncoMenopause Consortium®. The program will take place October 20, 2026, in San Diego, California, ahead of The Menopause Society's Annual Meeting.

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities

Dare Bioscience (NASDAQ: DARE - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Dare Bioscience and RYTHM's

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection